PubRank

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Clinical Trial ID NCT00556374

PubWeight™ 20.55‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00556374

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015 4.58
2 Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol 2010 1.27
3 Therapeutic targets for bone metastases in breast cancer. Breast Cancer Res 2011 1.16
4 Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmgenomics Pers Med 2014 1.09
5 The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist 2011 1.03
6 Management of cancer treatment-induced bone loss. Nat Rev Rheumatol 2013 0.99
7 Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis. J Hematol Oncol 2013 0.98
8 Cancer-associated bone disease. Osteoporos Int 2013 0.94
9 Tumour dormancy and clinical implications in breast cancer. Ecancermedicalscience 2013 0.92
10 Guidelines for Osteoprotection in Breast Cancer Patients on an Aromatase Inhibitor. Breast Care (Basel) 2010 0.92
11 Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer Patients. Breast Care (Basel) 2010 0.89
12 Breast Cancer: Rank Ligand Inhibition. Breast Care (Basel) 2010 0.88
13 Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer. Breast Cancer (Dove Med Press) 2016 0.87
14 Osteoporosis and cancer. Curr Osteoporos Rep 2013 0.80
15 Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion. Ther Adv Med Oncol 2011 0.79
16 Aromatase inhibitors-induced bone loss in early breast cancer. Bonekey Rep 2012 0.78
17 Importance of antiresorptive therapies for patients with bone metastases from solid tumors. Cancer Manag Res 2012 0.76
18 Impact of denosumab on bone mass in cancer patients. Clin Pharmacol 2013 0.75
19 Where Do Bone-Targeted Agents RANK in Breast Cancer Treatment? J Clin Med 2013 0.75
Next 100